All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub
Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EBMT 2023

By Helen Croxall

Share:

Apr 26, 2023

X post image

29 May 2023

🚨 #EBMT23 | In case you missed the @AML_Hub content from @TheEBMT 2023!

You can catch up via the link below 👇
https://t.co/YVflqia1oj

#AML #leukemia

View on 

X post image

26 Apr 2023

RT @MDS_Hub: Congress | #EBMT23 Raynier Devillier, @paoli_calmettes presents a phase II trial on the impact of higher doses of busulfan in…

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 Alexandros Spyridonidis @upatras discusses the validation of transplant conditioning intensity score for ASCT. The score provided a highly significant risk stratification for D100 and D180 NRM, 2-year NRM and REL risk (p<0.0001) #AMLsm #leukemia #medicalcongress

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Gianluca Cavallaro, ASST Papa Giovanni XXIII, presents a long-term analysis of the GITMO AML-R2 study. BuFlu conditioning was associated with a prolonged improvement in NRM, particularly in patients aged ≥51 years. #leusm

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Yishan Ye, @ZJU_China highlights an analysis of outcomes after allo-HSCT with different donor types in patients with AML with KMT2Ar. Haplo donors were associated with lower RI but higher NRM, resulting in similar LFS, OS, and GRFS as other donor types. #leusm

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Kordelia Barbullushi, @LaStatale presents a retrospective analysis of outcomes in pts with prAML who received allo-HSCT. Adverse cytogenetic risk, haploidentical donor, and longer time from diagnosis to allo-HSCT were associated with worse outcomes. #leusm

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Ali Bazarbachi @AUBMC_Official discusses the frequency and impact of somatic mutations on relapse and survival in pts with AML who underwent allo-HSCT. NGS at diagnosis can be beneficial for the risk stratification of pts with AML undergoing allo-HSCT. #leusm

View on 

X post image

26 Apr 2023

Congress | #EBMT23 @radovan_vrhovac University Hospital Centre Zagreb, presents an analysis of the impact of allo-HSCT in CR1 on OS from the QuANTUM-First trial. Quizartinib treatment and allo-HSCT in CR1 were associated with improved OS. #leusm #medicalcongress

View on 

X post image

26 Apr 2023

Congress | #EBMT23 @nourmoukalled @AUBMC_Official discusses a retrospective analysis of outcomes in pts with NPM1mut AML who underwent allo-HSCT based on cytogenetic status. Complex karyotype, not other adverse-risk normal cytogenetics, was associated with worse outcomes. #leusm

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Desiree Kunadt, @Medizin_TUD presents a retrospective analysis of patients with R/R AML with mutated FLT3 receiving salvage therapy with gilteritinib. Results indicate that gilteritinib maintenance therapy after allo-HSCT could improve survival. #leusm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2023European Society for Blood and Marrow Transplantation

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox